Fine particulate matter, known as PM 2.5, is recognized as a risk factor for dementia. 1 key finding →
Participants: 217,336 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Among 259 945 decedents with dementia (mean [SD] age, 85.8 [8.0] years; 60.4% female), 8.3% were non-Hispanic Black, 4.4% were Hispanic, and 87.3% were non-Hispanic White. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
51/100
The national combined PAF for 11 modifiable risk factors was 39.6 % (95 % CI: 20.8-55.9). 5 key findings →
Design: cross-sectional Participants: 86,494 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 934,792 individuals, 81,731 developed dementia over a mean follow-up of 11·6 years. 1 key finding →
Participants: 934,792 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global burden of AD and other dementias has significantly increased, with the highest incidence, prevalence, and DALYs observed in East Asia. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There was a significant difference in dementia incidence in the HSV-infected group versus the control. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over the last decade, age-standardised dementia incidence estimated rates have decreased by 52.8 % for women and 53.1 % for males. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We identified 132,968 individuals, of whom 12,088 with severe Zoster, 60,440 matched controls among the general population, and 60,440 matched controls among the hospitalised population. 5 key findings →
Participants: 132,968 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over a median follow-up of 8.2 years, YOD incidence increased progressively with higher WC. 5 key findings →
Participants: 964,536 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
51/100
We found positive associations between the 15 PM 2.5 components and the incidence of dementia and AD. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Neurological disorders are among the leading causes of both physical and cognitive disabilities worldwide, affecting approximately 15% of the global population. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment and dementia, including Alzheimer's disease (AD), pose a global health crisis, necessitating non-invasive biomarkers for early detection. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Advancing the understanding and management of Alzheimer's disease and related dementias requires integrating and analyzing diverse data modalities. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Actigraphy accurately identifies different dementia etiologies and could serve as a supplement to diagnostic investigations in patients with suspected AD for differential diagnostic purposes. 1 key finding →
Design: cross-sectional Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Machine learning (ML) on structural MRI data shows high potential for classifying Alzheimer's disease (AD) progression, but the specific contribution of brain regions, demographics, and proteinopathy remains unclear. 5 key findings →
Design: cross-sectional Participants: 568 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among the 18,013 participants with complete data for analysis, 516 (2.86%) exhibited cognitive impairment. 5 key findings →
Design: longitudinal study Participants: 27,768 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Seven studies were included from 1,800 screened. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We recruited 1501 participants (304 with FTLD, 512 with AD, and 685 healthy controls) from the Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat). 5 key findings →
Participants: 1,501 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Type 2 diabetes mellitus (T2DM) is associated with poorer cognitive performance and increased dementia risk. 2 key findings →
Participants: 9,943 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The DABNI cohort included 1,135 participants with a mean age of 42.82 years (SD = 11.56), 46.3% of whom are female. 5 key findings →
Design: longitudinal study Participants: 1,135 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Nuclear clearance and cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP-43) are observed in many neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
51/100
In the last few years, co-ultramicronized palmitoylethanolamide combined with luteoline has emerged as a potential therapeutic molecule in neurodegenerative disorders pathogenically related to frontotemporal dementia, for its demonstrated strong anti-inflammatory and neuroprotective properties. 4 key findings →
Design: clinical trial Participants: 25 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Plasma p-tau217 showed strong diagnostic performance for distinguishing AD from bvFTD (96% accuracy) and PPD (93% accuracy). 5 key findings →
Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aims to identify depressive risks in elderly individuals with subjective cognitive decline (SCD) and develop a predictive model using machine learning algorithms to enable timely interventions. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) is a significant and increasingly recognized problem in individuals with type 2 diabetes mellitus (T2DM). 2 key findings →
Design: prospective cohort Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →